A clinical pharmacologist is reviewing medication management protocols for a hospital system. Various clinical interventions and patient-specific factors necessitate adjustments in pharmacotherapy based on underlying pharmacokinetic principles. Match each clinical scenario or intervention on the left with its most accurate expected pharmacokinetic consequence on the right.
- Initiating intermittent hemodialysis for a patient on a medication with a volume of distribution () of and 98% plasma protein binding.Minimal increase in total extracorporeal clearance; supplemental post-procedural dosing is generally unnecessary.
- Doubling the continuous intravenous infusion rate of a medication that exhibits strict first-order elimination kinetics.The steady-state plasma concentration precisely doubles, but the time required to achieve this new steady state remains unchanged.
- Converting a medication known to undergo extensive hepatic first-pass metabolism from an oral formulation to a sublingual formulation.Substantial increase in systemic bioavailability (), necessitating a lower administered dose to achieve the same target serum concentration.
- Increasing the daily maintenance dose by 20% for a medication that strictly follows zero-order (capacity-limited) elimination kinetics.A disproportionate, non-linear elevation in steady-state plasma concentration, significantly increasing the risk of dose-dependent toxicity.
Answer
The clinical interventions dictate specific pharmacokinetic outcomes: high and high protein binding preclude hemodialysis clearance; first-order infusions alter but not the time to steady state; sublingual dosing bypasses first-pass metabolism to increase ; and zero-order drugs accumulate disproportionately with any dose increases.
Each clinical scenario strictly aligns with fundamental pharmacokinetic rules. High volume of distribution and extensive protein binding severely limit a drug's presence in the dialyzable plasma compartment. Sublingual dosing alters the anatomical absorption route to bypass hepatic enzymes, massively increasing bioavailability. First-order kinetics maintain a constant half-life, meaning time to steady state is unaffected by dose rate changes, whereas zero-order kinetics involve saturated enzymes that cannot accommodate dose increases proportionally.
Step-by-Step Solution
Key Concept
Clinical pharmacokinetics: dialyzability, infusion kinetics, first-pass metabolism, and capacity-limited elimination.